500213-34-3Relevant academic research and scientific papers
2-Substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b] isoquinolin-2(1H,3H,5H)-yl)acetic acids: Conformational prediction, synthesis, anti-thrombotic and vasodilative evaluation
Wang, Hong,Peng, Le,Zhao, Ming,Liu, Jiawang,Zhang, Xiaoyi,Wang, Yuji,Wu, Jianhui,Li, Li,Peng, Shiqi
, p. 871 - 882 (2011/03/19)
(S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic acid (TIC) can inhibit thrombosis by inhibiting platelet aggregation. The investigation of amino acids modified TIC reveals that a stretching conformation is critical for high anti-thrombotic activity. The conformational modeling shows that introducing a ring into amino acid modified TIC results in a desirable stretching conformation. According to this hypothesis, we synthesized seventeen novel 2-substituted (S)-2-(3,3-dimethyl-1-oxo-10,10a-dihydroimidazo[1,5-b]isoquinolin- 2(1H,3H,5H)-yl)acetic acids (5a-q). In the in vitro anti-platelet aggregation assay, for ADP-induced platelet aggregation the IC50 values of 5a-q are 1.8-3.4-folds lower than that of TIC. In the in vivo anti-thrombotic assay, the effective dose of 5a-q was 167-folds lower than that of TIC. The vessel strip assay showed that 5a-q had mild vasorelaxation activity.
Design, synthesis and biological evaluation of novel 1,2,3,4- tetrahydroisoquinoline-3-carboxylic acid derivatives as aminopeptidase N/CD13 inhibitors
Zhang, Xiaopan,Zhang, Jian,Zhang, Lei,Feng, Jinghong,Xu, Yingying,Yuan, Yumei,Fang, Hao,Xu, Wenfang
, p. 6015 - 6025 (2011/11/05)
A series of novel 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives were designed, synthesized and assayed for their activities against aminopeptidase N (APN/CD13) and MMP-2. The results showed that most compounds exhibited higher inhibitory activities against APN than that of MMP-2. Within this series, compound 12h (IC50 = 6.28 ± 0.11 μM) showed similar inhibitory activities compared with Bestatin (IC50 = 5.55 ± 0.01 μM), and it could be used as novel lead compound for the future APN inhibitors development as anticancer agents.
A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis
Cheng, Shenling,Zhang, Xiaoyi,Wang, Wei,Zhao, Ming,Zheng, Meiqing,Chang, Heng Wei,Wu, Jianghui,Peng, Shiqi
experimental part, p. 4904 - 4919 (2010/01/06)
To find new anti-thrombotic agents, a natural amino acid was introduced into the 3-position of anti-platelet aggregation active 3S-tetrahydroisoquinoline-3-carboxylic acid (THIQA), and 20 novel dipeptide derivatives, 3S-tetrahydroisoquinoline-3-carboxyamino acids (6a-t), targeting the intestinal peptide transport system were provided. In vitro anti-platelet aggregation assay of 6a-t indicated that their potencies of inhibiting adenosine diphosphate (ADP), arachidonic acid (AA), platelet-activating factor (PAF), and thrombin (TH) induced platelet aggregations were higher than that of THIQA, and the in vivo anti-thrombotic assay of 6a-t indicated that their potencies of inhibiting thrombogenesis in rats were also higher than that of THIQA. According to MFA based Cerius2 QSAR module, using training/test set of 6a,b,d,g-p/6c,e,f,q and training/test set of 6a-p/6q-t, two equations (r, 0.984 and 0.996) correlating the structures with in vitro or in vivo activity of 6a-t were established.
Novel antibiotics: C-2 symmetrical macrocycles inhibiting Holliday junction DNA binding by E. coli RuvC
Pan, Po-Shen,Curtis, Fiona A.,Carroll, Chris L.,Medina, Irene,Liotta, Lisa A.,Sharples, Gary J.,McAlpine, Shelli R.
, p. 4731 - 4739 (2007/10/03)
Holliday junctions (HJs) are formed as transient DNA intermediates during site-specific and homologous recombination. Both of these genetic exchange pathways are critical for normal DNA metabolism and repair. Trapping HJs leads to bacterial cell death by
A progressive synthetic strategy for class B synergimycins
Robinson, Jennifer L.,Taylor, Rachel E.,Liotta, Lisa A.,Bolla, Megan L.,Azevedo, Enrique V.,Medina, Irene,McAlpine, Shelli R.
, p. 2147 - 2150 (2007/10/03)
Described are the syntheses of four macrocyclic peptides that are the core structure of class B synergimycins, and the synthesis of a final class B derivative. Our synthetic route to these synergimycin derivatives allows the incorporation of amino acid su
Novel antibiotics: Second generation macrocyclic peptides designed to trap Holliday junctions
Liotta, Lisa A.,Medina, Irene,Robinson, Jennifer L.,Carroll, Chris L.,Pan, Po-Shen,Corral, Ricardo,Johnston, Jennifer V.C.,Cook, Kristina M.,Curtis, Fiona A.,Sharples, Gary J.,McAlpine, Shelli R.
, p. 8447 - 8450 (2007/10/03)
Described are the syntheses of 15 macrocyclic peptides designed to trap Holliday junctions (HJs) in bacteria during site-specific and homologous recombination. This leads to inhibiting bacterial growth. These second generation macrocycles were based on th
Novel antibiotics: macrocyclic peptides designed to trap Holliday junctions.
Bolla, Megan L,Azevedo, Enrique V,Smith, Jason M,Taylor, Rachel E,Ranjit, Dev K,Segall, Anca M,McAlpine, Shelli R
, p. 109 - 112 (2007/10/03)
[reaction: see text] Described are the syntheses of eight macrocyclic peptides designed to trap Holliday junctions in bacteria, thereby inhibiting bacterial growth. These macrocycles were designed from linear dimerized hexapeptides that bind to the C-2 sy
